Chemotherapy response score as a predictor of survival in ovarian cancer patients
Ovarian cancer is the main cause of mortality among gynecological cancer patients, accounting for more than 200,000 new cases annually at an international level and responsible for more than 150,000 deaths [1]. It is usually encountered in advanced stages, as symptomatology is primarily of an obstructive nature from the gastrointestinal system or the respiratory tract, depending on the site of metastases, the involvement of the bowel tract, and the severity of ascites [2]. The symptomatology in patients with early-stage disease may exceed rates of 50 % of those affected; however, it is usually subtle and may be overlooked by both patients and physicians [3].
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Ioannis Rodolakis, Michalis Liontos, Vasilios Pergialiotis, Dimitrios Haidopoulos, Maria Kaparelou, Dimitrios Efthimios Vlachos, Meletios Athanasios Dimopoulos, Dimitrios Loutradis, Alexandros Rodolakis, Aristotelis Bamias, Nikolaos Thomakos Tags: Full length article Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | OBGYN | Ovarian Cancer | Ovaries | Respiratory Medicine